No

Stimulant

Attention-deficit disorder with hyperactivity; narcolepsy

C

Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncrasy to the sympathomimetic amines; glaucoma; agitated states; patients with a history of drug abuse; during or within 14 days following MAOI (hypertensive crisis)

When tolerance to the anorectic effect develops, the recommended dose should not be exceeded in attempt to increase the effect; rather the drug should be discontinued. Use caution in mildly hypertensive patients; amphetamines may impair the ability to engage in potentially hazardous activities.

Cardiovascular: Palpitations, tachycardia, hypertension, cardiomyopathy

Central nervous system: Overstimulation, euphoria, dyskinesia, dysphoria, exacerbation of motor and phonic tics, restlessness, insomnia, dizziness, headache, psychosis, Tourette's syndrome

Dermatologic: Rash, urticaria

Endocrine & metabolic: Changes in libido

Gastrointestinal: Diarrhea, constipation, anorexia, weight loss, xerostomia, unpleasant taste

Genitourinary: Impotence

Neuromuscular & skeletal: Tremor

Amphetamines inhibit the antihypertensive response to guanethidine and guanadrel; consider alternate agents

May precipitate hypertensive crisis or serotonin syndrome in patients receiving MAO inhibitors (selegiline >10 mg/day, isocarboxazid, phenelzine, tranylcypromine, furazolidone). This combination should be avoided

Large doses of antacids (sodium bicarbonate) may inhibit the elimination of dextroamphetamine and increase its effects

TCAs may enhance the effects of amphetamines; avoid use or monitor for CV effects

Urinary acidifiers decrease the half-life and duration of action of amphetamines; dose adjustment may be necessary

Urinary alkalinizers increase the half-life and duration of action of amphetamines; dosage decrease may be necessary

Blocks reuptake of dopamine and norepinephrine from the synapse, thus increases the amount of circulating dopamine and norepinephrine in cerebral cortex to reticular activating system; inhibits the action of monoamine oxidase and causes catecholamines to be released. Peripheral actions include elevated blood pressure, weak bronchodilator, and respiratory stimulant action.

Oral:

Children:

6-12 years: 5 mg/day, increase by 5 mg at weekly intervals

>12 years: 10 mg/day, increase by 10 mg at weekly intervals

Adults: 5-60 mg/day in 2-3 divided doses

Attention deficit/hyperactivity disorder: Children:

3-5 years: 2.5 mg/day, increase by 2.5 mg at weekly intervals

>6 years: 5 mg/day, increase by 5 mg at weekly intervals not to exceed 40 mg/day

Short-term adjunct to exogenous obesity: Children >12 years and Adults: 5-30 mg/day in divided doses

Use vasoconstriction with caution in patients taking dextroamphetamine. Amphetamines enhance the sympathomimetic response of epinephrine and norepinephrine leading to potential hypertension and cardiotoxicity.

Up to 10% of patients taking dextroamphetamines may present with hypertension. The use of local anesthetic without vasoconstrictor is recommended in these patients.

Tablet:

30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg and amphetamine aspartate 7.55 mg, amphetamine sulfate 7.5 mg]